Pioneering mRNA technology - Moderna
Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines.
Moderna - Wikipedia
Moderna, Inc. (/ m ə ˈ d ɜːr n ə / mə-DUR-nə) [4] is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines.
Our Story - Moderna
We’re making biotech history. Since 2010, we have worked to build the industry's leading mRNA technology platform. Learn more about Moderna’s history.
HHS invests nearly $600 million in Moderna’s bird flu vaccine ...
4 hours ago · The US Department of Health and Human Services will award $590 million to Moderna to continue developing a vaccine to protect against bird flu, the pharmaceutical company announced Friday.
US awards Moderna $590 million for bird flu vaccine development
5 hours ago · The U.S. government has awarded Moderna $590 million to advance the late-stage development of its mRNA bird flu vaccine, as the country doubles down on efforts to tackle increasing infections in ...
mRNA medicines we are currently developing - Moderna
Track the development of Moderna’s mRNA medicines. From preclinical development to commercial phase.
Moderna Achieves Positive Interim Results from Phase 3 Trial of …
Mar 26, 2024 · Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases.
Moderna Advances Multiple Vaccine Programs to Late-Stage …
Mar 27, 2024 · Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases.
Moderna Expands the Field of mRNA Medicine with Positive …
Sep 13, 2023 · Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases.
Moderna Announces Advances Across Its Industry-Leading mRNA …
Jan 10, 2022 · Moderna announced a new strategic collaboration agreement with Carisma Therapeutics, Inc. to discover, develop and commercialize in vivo engineered chimeric antigen receptor monocyte (CAR-M) therapeutics for the treatment of cancer, including solid tumors.
- Some results have been removed